C4 Therapeutics Stock Market Value
| CCCC Stock | USD 4.05 0.10 2.41% |
| Symbol | CCCC |
C4 Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.522 | Quarterly Revenue Growth 0.387 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
C4 Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to C4 Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of C4 Therapeutics.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in C4 Therapeutics on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding C4 Therapeutics or generate 0.0% return on investment in C4 Therapeutics over 30 days. C4 Therapeutics is related to or competes with Shattuck Labs, Eliem Therapeutics, Prelude Therapeutics, Monte Rosa, Foghorn Therapeutics, Rezolute, and Century Therapeutics. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade dise... More
C4 Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure C4 Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess C4 Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 23.66 | |||
| Value At Risk | (7.98) | |||
| Potential Upside | 9.57 |
C4 Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for C4 Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as C4 Therapeutics' standard deviation. In reality, there are many statistical measures that can use C4 Therapeutics historical prices to predict the future C4 Therapeutics' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (1.15) | |||
| Treynor Ratio | (1.62) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of C4 Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
C4 Therapeutics Backtested Returns
C4 Therapeutics retains Efficiency (Sharpe Ratio) of -0.15, which signifies that the company had a -0.15% return per unit of price deviation over the last 3 months. C4 Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm C4 Therapeutics' Variance of 25.66, market risk adjusted performance of (1.61), and Information Ratio of (0.12) to double-check the risk estimate we provide. The firm owns a Beta (Systematic Risk) of 0.3, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, C4 Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding C4 Therapeutics is expected to be smaller as well. At this point, C4 Therapeutics has a negative expected return of -0.73%. Please make sure to confirm C4 Therapeutics' total risk alpha, potential upside, and the relationship between the standard deviation and maximum drawdown , to decide if C4 Therapeutics performance from the past will be repeated sooner or later.
Auto-correlation | 0.10 |
Insignificant predictability
C4 Therapeutics has insignificant predictability. Overlapping area represents the amount of predictability between C4 Therapeutics time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of C4 Therapeutics price movement. The serial correlation of 0.1 indicates that less than 10.0% of current C4 Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.1 | |
| Spearman Rank Test | -0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.63 |
C4 Therapeutics lagged returns against current returns
Autocorrelation, which is C4 Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting C4 Therapeutics' stock expected returns. We can calculate the autocorrelation of C4 Therapeutics returns to help us make a trade decision. For example, suppose you find that C4 Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
C4 Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If C4 Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if C4 Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in C4 Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
C4 Therapeutics Lagged Returns
When evaluating C4 Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of C4 Therapeutics stock have on its future price. C4 Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, C4 Therapeutics autocorrelation shows the relationship between C4 Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in C4 Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out C4 Therapeutics Correlation, C4 Therapeutics Volatility and C4 Therapeutics Alpha and Beta module to complement your research on C4 Therapeutics. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
C4 Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.